Company news

Regeneron Pharmaceuticals, Inc. news in 2021

Regeneron Pharmaceuticals, Inc.'s news releases, calls and decks from 2021, newest first.

View company

Regeneron Announces Presentation at the 40th Annual J.P. Morgan Healthcare Conference

December 21, 2021

New REGN5458 (BCMAxCD3) Phase 1 Data Show 75% Response Rate at Highest Dose Levels Studied in Patients with Heavily Pretreated Multiple Myeloma

December 10, 2021

Regeneron Announces $3 Billion Share Repurchase Program

November 11, 2021

New Phase 3 Analyses Show That a Single Dose of REGEN-COV® (casirivimab and imdevimab) Provides Long-term Protection Against COVID-19

November 7, 2021

Regeneron Reports Third Quarter 2021 Financial and Operating Results

November 3, 2021

Second Dupixent® (dupilumab) Phase 3 Eosinophilic Esophagitis Trial to Demonstrate Significant Disease Improvements, Underscoring Role of Type 2 Inflammation in This Complex Disease

October 24, 2021

Dupixent® (dupilumab) is the First Biologic to Significantly Reduce Itch and Skin Lesions in Phase 3 Trial for Prurigo Nodularis, Demonstrating the Role of Type 2 Inflammation in this Disease

October 21, 2021

FDA Expands Approval of Dupixent® (dupilumab) to Include Children Aged 6 to 11 Years with Moderate-to-severe Asthma

October 19, 2021

FDA Accepts REGEN-COV® (casirivimab and imdevimab) for Priority Review for Treatment and Prophylaxis of COVID-19

October 13, 2021

Regeneron to Report Third Quarter 2021 Financial and Operating Results and Host Conference Call and Webcast on November 4, 2021

October 10, 2021

FDA Accepts Libtayo® (cemiplimab-rwlc) for Priority Review for Advanced Cervical Cancer

September 27, 2021

Regeneron Announces New U.S. Government Agreement to Purchase Additional Doses of REGEN-COV™ (casirivimab and imdevimab) Antibody Cocktail

September 13, 2021

Dupixent® (dupilumab) Pivotal Trial Meets All Primary and Secondary Endpoints Becoming First Biologic Medicine to Significantly Reduce Signs and Symptoms of Moderate-to-severe Atopic Dermatitis in Children as Young as 6 Months

August 29, 2021

Regeneron Announces Encouraging Topline Phase 2 Data of High-dose aflibercept in Wet Age-related Macular Degeneration

August 23, 2021

Regeneron Reports Second Quarter 2021 Financial and Operating Results

August 4, 2021

Regeneron Announces the 2021 Winners of the Regeneron Prize for Creative Innovation

August 2, 2021

Dupixent® (dupilumab) Significantly Improved Itch and Hives in Patients with Chronic Spontaneous Urticaria, a Step Forward in Demonstrating the Role of Type 2 Inflammation in These Patients

July 28, 2021

Regeneron and AstraZeneca to Research, Develop and Commercialize New Small Molecule Medicines for Obesity

July 26, 2021

Japan Becomes First Country to Approve Regeneron Antibody Cocktail (casirivimab and imdevimab) for the Treatment of Mild to Moderate COVID-19

July 19, 2021

Regeneron to Report Second Quarter 2021 Financial and Operating Results and Host Conference Call and Webcast on August 5, 2021

July 6, 2021

Regeneron Genetics Center Discovers GPR75 Gene Mutations that Protect Against Obesity

June 30, 2021

Libtayo® (cemiplimab) Approved by the European Commission as the First Immunotherapy Indicated for Patients with Advanced Basal Cell Carcinoma

June 24, 2021

REGEN-COV™ (casirivimab and imdevimab) Phase 3 RECOVERY Trial Meets Primary Outcome, Improving Survival in Hospitalized COVID-19 Patients Lacking an Immune Response to SARS-CoV-2

June 15, 2021

Libtayo® (cemiplimab) Receives Positive CHMP Opinion for the Treatment in Europe of Two Advanced Cancers

May 23, 2021

Regeneron Reports First Quarter 2021 Financial and Operating Results

May 5, 2021

Phase 3 Treatment Trial in Recently Infected Asymptomatic Patients Showed REGEN-COV™ (casirivimab with imdevimab) Significantly Reduced Progression to Symptomatic COVID-19

April 11, 2021

Regeneron to Report First Quarter 2021 Financial and Operating Results and Host Conference Call and Webcast on May 6, 2021

April 5, 2021

Phase 3 Trial Shows REGEN-COV™ (casirivimab with imdevimab) Antibody Cocktail Reduced Hospitalization or Death by 70% in Non-hospitalized COVID-19 Patients

March 22, 2021

FDA Accepts Dupixent® (dupilumab) for Review in Children with Moderate-to-severe Asthma

March 3, 2021

Regeneron Announces Positive Phase 2 Data Evaluating Fel d 1 Antibody Cocktail in Cat-allergic Patients with Mild Asthma

February 26, 2021

Independent Data Monitoring Committee Finds Clear Efficacy for REGEN-COV™ (casirivimab with imdevimab) in Phase 3 COVID-19 Outpatient Outcomes Trial

February 24, 2021

FDA Approves Libtayo® (cemiplimab-rwlc) as First Immunotherapy Indicated for Patients with Advanced Basal Cell Carcinoma

February 8, 2021

Regeneron Reports Fourth Quarter and Full Year 2020 Financial and Operating Results

February 4, 2021

REGEN-COV™ Antibody Cocktail Is Active Against SARS-CoV-2 Variants First Identified in the UK and South Africa

January 26, 2021

Regeneron Reports Positive Interim Data with REGEN-COV™ Antibody Cocktail used as Passive Vaccine to Prevent COVID-19

January 25, 2021

Regeneron to Report Fourth Quarter and Full Year 2020 Financial and Operating Results and Host Conference Call and Webcast on February 5, 2021

January 18, 2021

Regeneron Announces U.S. Government Agreement to Purchase Additional COVID-19 Antibody Cocktail Doses

January 11, 2021

Calls in 2021

Decks in 2021